Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025220 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
A Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00025220: Completed Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by National Cancer Institute (NCI).
NCT00025220 is a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025220, a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Thalidomide
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-09 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00025220 record still lists
NCT00025220 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Uterine Corpus Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00025220 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00025220 about?
NCT00025220 is a clinical study titled "Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus". Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
What is the current status of trial NCT00025220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-09. Estimated completion is 2008-07.
What conditions does trial NCT00025220 study?
This clinical trial studies the following conditions: Uterine Corpus Leiomyosarcoma, Recurrent Uterine Corpus Sarcoma.
What interventions are being tested in trial NCT00025220?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00025220?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025220 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Corpus Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00025220's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia